Table 1.
Liver biopsy | Noninvasive markers | |
Advantages | ||
Validated scoring systems | Absence of significant discomfort and risks | |
Differential diagnosis and associated conditions | Allows frequent re-evaluation | |
Simultaneous evaluation of necro-inflammation | Objective interpretation | |
Patient acceptance | ||
Limitations | ||
Invasive | Low accuracy to discriminate between intermediate stages of fibrosis | |
High cost | Nonspecific for the liver (biomarkers) | |
Sampling errors and intra- and inter-observer variability | Influence of several extra-hepatic factors |